Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 5, 2020The Lancet OncologyOpen Access

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJean‐Yves BlayCSCésar SerranoMHMichael C. Heinrich

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blay et al. (2020) studied this question.

synapsesocial.com/papers/6a9ebf01972e27e66c478bdbhttps://doi.org/10.1016/s1470-2045(20)30168-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review2017 · 99 citations
  2. 2Interpretation of Changes in Health-related Quality of Life2003 · 4,735 citations
  3. 3Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients2014 · 161 citations
  4. 4Heterogeneity of kinase inhibitor resistance mechanisms in GIST2008 · 463 citations
  5. 5Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours2019 · 172 citations